Liu J, Guo YP, Lu YM, Wang BL. Clinical value of combining epirubicin with mindfulness intervention in patients with urinary system tumors and depression. World J Psychiatry 2025; 15(1): 98737 [DOI: 10.5498/wjp.v15.i1.98737]
Corresponding Author of This Article
Juan Liu, MBBS, Nurse, Department of Urology Surgery, Zhumadian Central Hospital, No. 747 Zhonghua Road, Zhumadian 463000, Henan Province, China. liujuan0396@163.com
Research Domain of This Article
Psychiatry
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Psychiatry. Jan 19, 2025; 15(1): 98737 Published online Jan 19, 2025. doi: 10.5498/wjp.v15.i1.98737
Clinical value of combining epirubicin with mindfulness intervention in patients with urinary system tumors and depression
Juan Liu, Yan-Ping Guo, Yan-Mei Lu, Bei-Lin Wang
Juan Liu, Yan-Mei Lu, Bei-Lin Wang, Department of Urology Surgery, Zhumadian Central Hospital, Zhumadian 463000, Henan Province, China
Yan-Ping Guo, Department of Psychiatry, Zhumadian Mental Hospital, Zhumadian 463000, Henan Province, China
Author contributions: Liu J and Guo YP conceived this study, Lu YM collected and organized clinical data, and Wang BL conducted statistical analysis.
Institutional review board statement: The study was reviewed and approved by the Institutional Review Board of Zhumadian Central Hospital.
Informed consent statement: The Institutional Review Board approved an exemption from informed consent.
Conflict-of-interest statement: The authors declare no conflict of interest.
Data sharing statement: The data used in this study can be obtained from the corresponding author upon request.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Juan Liu, MBBS, Nurse, Department of Urology Surgery, Zhumadian Central Hospital, No. 747 Zhonghua Road, Zhumadian 463000, Henan Province, China. liujuan0396@163.com
Received: September 12, 2024 Revised: October 10, 2024 Accepted: October 18, 2024 Published online: January 19, 2025 Processing time: 97 Days and 0.4 Hours
Abstract
BACKGROUND
Urinary system tumors often cause negative psychological symptoms, such as depression and dysphoria which significantly impact immune function and indirectly affect cancer prognosis. While epirubicin (EPI) is recommended by the European Association of Urology and can improve prognosis, its long-term use can cause toxic side effects, reduce treatment compliance, and increase psychological burden. Therefore, an appropriate intervention mode is necessary.
AIM
To explore the clinical value of EPI combined with mindfulness intervention in patients with urinary system tumors and depression.
METHODS
This was a retrospective study including 110 patients with urinary system tumors and depression admitted to Zhumadian Central Hospital between March 2021 and July 2023. Patients were divided into conventional (n = 55) and joint intervention (n = 55) groups. The conventional group received mitomycin and routine nursing, while the joint intervention group received EPI and mindfulness intervention. Both groups underwent three cycles of chemotherapy. Immune function (CD4+ cells, CD8+ cells, CD4+/CD8+ ratio), tumor marker levels [urinary bladder cancer antigen (UBC), bladder tumor antigen (BTA) and nuclear matrix protein 22 (NMP22)], quality of life questionnaire-core 30 (QLQ-C30), 17-item Hamilton depression scale (HAMD-17), and cancer-related fatigue [cancer fatigue scale (CFS)] were assessed. Adverse reactions and nursing satisfaction were recorded and evaluated.
RESULTS
Post-intervention, CD4+, CD8+, and CD4+/CD8+ levels increased in both groups, with the joint intervention group showing more significant improvement (P < 0.05). Tumor marker levels (NMP22, BTA, and UBC) were lower in the joint intervention group compared to the conventional group (P < 0.05). The joint intervention group also showed a greater reduction in HAMD-17 scores (9.38 ± 3.12 vs 15.45 ± 4.86, P < 0.05), higher QLQ-C30 scores, and lower CFS scores (both P < 0.05). Additionally, the joint intervention group had a lower incidence of adverse reactions and higher nursing satisfaction (P < 0.05).
CONCLUSION
EPI combined with mindfulness intervention significantly improved clinical outcomes in patients with urinary system tumors and depression and is worthy of clinical application.
Core Tip: Urinary system tumors often cause varying degrees of negative psychological symptoms, such as depression and dysphoria. These psychological factors significantly impact patients’ immune function and indirectly affect the intervention and prognosis of patients with cancer. Epirubicin (EPI) can improve the prognosis of patients with urinary system tumors, but it also has certain side effects. Mindfulness interventions are beneficial for enhancing psychological adaptability in cancer patients. In this study, the combination of EPI and mindfulness intervention achieved remarkable clinical results in patients with depression-complicated urinary system tumors.
